Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Sovaldi/Harvoni

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Sovaldi/Harvoni was produced by Gilead Sciences.

NHS England sees off AbbVie's Hep C legal challenge

NHS England sees off AbbVie's Hep C legal challenge

Maviret is in contention with rival treatments such as Gilead’s Sovaldi, Harvoni and Epclusa, to name a few.

Torrid times at Gilead lead to calls for a major M&A deal

Torrid times at Gilead lead to calls for a major M&A deal Sales of its hepatitis drugs Sovaldi, Harvoni and Epclusa were down $1.5bn in the same period of 2015 to $3.3bn, with overall revenues down almost 10% to $7.5bn

Gilead’s hepatitis C sales start to slide – the question is how quickly?

Gilead’s hepatitis C sales start to slide – the question is how quickly? The US pharma company has reaped the benefits of stellar sales for its directly-acting HCV therapies since it first launched Sovaldi (sofosbuvir) in 2013 and two-drug follow-up Harvoni

European pharma ‘to grow 3.2% per year by 2022’

European pharma ‘to grow 3.2% per year by 2022’ In hepatitis C, Gilead's Sovaldi (2015: 1.443 bn; 2022: 609m) and its follow-up therapy Harvoni (2015: 2 bn; 2022: 887m) million) will struggle due to price pressure and

FDA approves Gilead's 'universal' hep C combination Epclusa

FDA approves Gilead's 'universal' hep C combination Epclusa Epclusa joins Sovaldi and Harvoni (sofosbuvir/ledipasvir), a product specifically indicated for patients with hepatitis C virus genotype 1 infection, in Gilead's hep C portfolio. ... Sovaldi and Harvoni brought in sales of $5.3bn and $13.9bn respectively

1 2 3 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics